GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » 3-Year ROIIC %

CollPlant Biotechnologies (CollPlant Biotechnologies) 3-Year ROIIC % : -134.06% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. CollPlant Biotechnologies's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -134.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for CollPlant Biotechnologies's 3-Year ROIIC % or its related term are showing as below:

CLGN's 3-Year ROIIC % is ranked worse than
72.23% of 1419 companies
in the Biotechnology industry
Industry Median: -13.44 vs CLGN: -134.06

CollPlant Biotechnologies 3-Year ROIIC % Historical Data

The historical data trend for CollPlant Biotechnologies's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies 3-Year ROIIC % Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.70 6.85 88.48 6,395.95 -134.06

CollPlant Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -134.06 -

Competitive Comparison of CollPlant Biotechnologies's 3-Year ROIIC %

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year ROIIC % falls into.



CollPlant Biotechnologies 3-Year ROIIC % Calculation

CollPlant Biotechnologies's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -7.512 (Dec. 2023) - -5.599 (Dec. 2020) )/( 8.27 (Dec. 2023) - 6.843 (Dec. 2020) )
=-1.913/1.427
=-134.06%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CollPlant Biotechnologies  (NAS:CLGN) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


CollPlant Biotechnologies 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (CollPlant Biotechnologies) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.